Ratings by Morgan Stanley (Sarita Kapila)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | AstraZeneca | AZN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Sanofi | SNY | Downgrade | Equalweight (Overweight) |
46.58 (42.89) |
-7.92% | Details | |
| 4/24/2026 | Roche | RHHBY | Upgrade | Equalweight (Underweight) |
51.20 (56.17) |
9.71% | Details | |
| 4/7/2026 | AstraZeneca | AZN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/7/2026 | Roche | RHHBY | Maintain | Underweight (N/A) |
|
Details | ||
| 3/31/2026 | Sanofi | SNY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2025 | Sanofi | SNY | Upgrade | Overweight (Equalweight) |
45.33 (46.58) |
2.76% | Details | |
| 8/8/2025 | Roche | RHHBY | Downgrade | Underweight (Equalweight) |
38.36 (51.20) |
33.47% | Details |
